• 제목/요약/키워드: pulmonary disease chronic obstructive

검색결과 513건 처리시간 0.031초

만성폐쇄성폐질환환자 1례에 대한 임상적 고찰 (The clinical study of chronic obstructive pulmonary disease)

  • 김주성;임성우;손정숙
    • 대한한방내과학회지
    • /
    • 제21권3호
    • /
    • pp.525-528
    • /
    • 2000
  • We report the treatment case of patient for chronic obstructive pulmonary disease. The patient was 65 year-old woman with the history of smoking and asthma. She had complained of dyspnea, hyperpnea, cough and wheezing sound. We treated her with general management, bronchodilator and five kinds of herbal medicine(Samjahwadamjeon etc). Among them, the major herbal medicine is Samjahwadamjeon. Having been treated for 35 days, the patient improved in clinical symptoms and pulmonary function in PFT(Pulmonary function test).

  • PDF

만성폐쇄성폐질환과 수면장애 (Chronic Obstructive Pulmonary Disease and Sleep Disorder)

  • 김세원;강현희
    • 수면정신생리
    • /
    • 제27권1호
    • /
    • pp.8-15
    • /
    • 2020
  • Sleep disorder in chronic obstructive pulmonary disease (COPD) is common and typically is associated with oxygen desaturation. The mechanisms of desaturation include hypoventilation and ventilation to perfusion mismatch. Despite the importance of sleep in patients with COPD, this topic is under-assessed in clinical practice. Impaired sleep quality is associated with more severe COPD and may contribute to worse clinical outcomes. Recent data have indicated that specific respiratory management of patients with COPD and sleep disordered breathing improves clinical outcomes. Clinicians managing patients with COPD should pay attention to and actively manage symptoms of comorbid sleep disorders. Management of sleep-related problems in COPD should particularly focus on minimizing sleep disturbance.

Evaluation and interpretation of transcriptome data underlying heterogeneous chronic obstructive pulmonary disease

  • Ham, Seokjin;Oh, Yeon-Mok;Roh, Tae-Young
    • Genomics & Informatics
    • /
    • 제17권1호
    • /
    • pp.2.1-2.12
    • /
    • 2019
  • Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease, featured by airflow obstruction. Recently, a comprehensive analysis of the transcriptome in lung tissue of COPD patients was performed, but the heterogeneity of the sample was not seriously considered in characterizing the mechanistic dysregulation of COPD. Here, we established a new transcriptome analysis pipeline using a deconvolution process to reduce the heterogeneity and clearly identified that these transcriptome data originated from the mild or moderate stage of COPD patients. Differentially expressed or co-expressed genes in the protein interaction subnetworks were linked with mitochondrial dysfunction and the immune response, as expected. Computational protein localization prediction revealed that 19 proteins showing changes in subcellular localization were mostly related to mitochondria, suggesting that mislocalization of mitochondria-targeting proteins plays an important role in COPD pathology. Our extensive evaluation of COPD transcriptome data could provide guidelines for analyzing heterogeneous gene expression profiles and classifying potential candidate genes that are responsible for the pathogenesis of COPD.

Prediction of Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Quantitative CT Parameters

  • Hyun Jung Koo;Sang Min Lee;Joon Beom Seo;Sang Min Lee;Namkug Kim;Sang Young Oh;Jae Seung Lee;Yeon-Mok Oh
    • Korean Journal of Radiology
    • /
    • 제20권4호
    • /
    • pp.683-692
    • /
    • 2019
  • Objective: We aimed to evaluate correlations between computed tomography (CT) parameters and pulmonary function test (PFT) parameters according to disease severity in patients with chronic obstructive pulmonary disease (COPD), and to determine whether CT parameters can be used to predict PFT indices. Materials and Methods: A total of 370 patients with COPD were grouped based on disease severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) I-IV criteria. Emphysema index (EI), air-trapping index, and airway parameters such as the square root of wall area of a hypothetical airway with an internal perimeter of 10 mm (Pi10) were measured using automatic segmentation software. Clinical characteristics including PFT results and quantitative CT parameters according to GOLD criteria were compared using ANOVA. The correlations between CT parameters and PFT indices, including the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) and FEV1, were assessed. To evaluate whether CT parameters can be used to predict PFT indices, multiple linear regression analyses were performed for all patients, Group 1 (GOLD I and II), and Group 2 (GOLD III and IV). Results: Pulmonary function deteriorated with increase in disease severity according to the GOLD criteria (p < 0.001). Parenchymal attenuation parameters were significantly worse in patients with higher GOLD stages (P < 0.001), and Pi10 was highest for patients with GOLD III (4.41 ± 0.94 mm). Airway parameters were nonlinearly correlated with PFT results, and Pi10 demonstrated mild correlation with FEV1/FVC in patients with GOLD II and III (r = 0.16, p = 0.06 and r = 0.21, p = 0.04, respectively). Parenchymal attenuation parameters, airway parameters, EI, and Pi10 were identified as predictors of FEV1/FVC for the entire study sample and for Group 1 (R2 = 0.38 and 0.22, respectively; p < 0.001). However, only parenchymal attenuation parameter, EI, was identified as a predictor of FEV1/FVC for Group 2 (R2 = 0.37, p < 0.001). Similar results were obtained for FEV1. Conclusion: Airway and parenchymal attenuation parameters are independent predictors of pulmonary function in patients with mild COPD, whereas parenchymal attenuation parameters are dominant independent predictors of pulmonary function in patients with severe COPD.

만성폐쇄성폐질환 환자 사망 원인 - 한 3차 병원 연구 (Cause of Death in COPD Patients of a Referral Hospital)

  • 김범준;홍상범;심태선;임채만;이상도;고윤석;김우성;김동순;김원동;오연목
    • Tuberculosis and Respiratory Diseases
    • /
    • 제60권5호
    • /
    • pp.510-515
    • /
    • 2006
  • 연구 배경 : 만성폐쇄성폐질환(COPD)은 45세 이상의 성인에서 국내 유병률 17.2%로 주요 질환이다. 하지만, 국내 COPD 환자의 사망원인에 대한 연구는 불충분한 상황이다. 이에 국내 COPD 환자 사망원인에 대해서 알아보고자 서울아산병원 의무기록을 후향적으로 조사하였다. 방 법 : 2003년 1년간 서울아산병원에서 COPD로 진료한 1,078명의 사망여부를 통계청에 의뢰하여 총 사망자 88명을 얻었고 이중 폐결핵 후유증, 기관지확장증, 폐암 등 암 환자를 제외한 후 남은 28명의 COPD 환자 대상으로 사망원인을 분석하였다. 결 과 : COPD 환자의 사망원인은 폐렴 등 호흡기 원인이 16명 (57%), 심장 원인 5명 (18%), 급사 3명 (11%), 기타 4명 (14%) 등이었다. 서울아산병원 내에서 사망한 환자와 외에서 사망한 환자의 호흡기 관련 사망이 각각 83%(10명/12명)과 38%(6명/16명)이었다 (P=0.05) $FEV_1$이 50%예측치보다 큰 환자와 작은 환자의 호흡기 관련 사망은 각각 43%과 55%이었다 (P=0.89). 결 론 : 국내 3차 병원에서 진료하는 COPD 환자의 사망 원인은 폐렴 등 호흡기 원인 다수를 차지한다.

만성폐쇄성폐질환 유소견 성인의 폐쇄성 기류제한 상태 비인지 영향요인 (Risk Factors for Unawareness of Obstructive Airflow Limitation among Adults with Chronic Obstructive Pulmonary Disease)

  • 조미래;오희영
    • 지역사회간호학회지
    • /
    • 제29권3호
    • /
    • pp.290-299
    • /
    • 2018
  • Purpose: The purpose of the present study is to examine risk factors for unawareness of obstructive airflow limitation among adults with chronic obstructive pulmonary disease. Methods: Secondary data analysis was performed with the data from the 6th Korea National Health and Nutrition Examination Survey (KNHANES; 2013-2014). The data were analyzed with the IBM SPSS 22.0 version using frequency, percentage, odds ratio, and logistic regression. Results: Ninety-eight percent of subject with a pulmonary function test score of $FEV_1/FVC$<0.7 (N=833) did not recognize that their lung function was impaired. The heavy drink, absence of tuberculosis or asthma diagnosis, and no symptom of expelling phlegm were identified as major risk factors for unawareness of airflow limitation. Conclusion: In order to increase awareness of airflow limitation and to prevent the worsening of the condition, the pulmonary function screening test should be provided to community residents including those who do not show symptoms of respiratory illness.

Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?

  • Bouazza, Belaid;Hadj-Said, Dihia;Pescatore, Karen A.;Chahed, Rachid
    • Tuberculosis and Respiratory Diseases
    • /
    • 제84권1호
    • /
    • pp.22-34
    • /
    • 2021
  • The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic.

Different Pattern of Chronic Obstructive Pulmonary Disease Assessment Test Score between Chronic Bronchitis and Non-chronic Bronchitis Patients

  • Yoo, Sang Hoon;Lee, Jae Ha;Yoo, Kwang Ha;Jung, Ki-Suck;Rhee, Chin Kook
    • Tuberculosis and Respiratory Diseases
    • /
    • 제81권3호
    • /
    • pp.228-232
    • /
    • 2018
  • Background: Chronic bronchitis (CB) is an important phenotype in chronic obstructive pulmonary disease (COPD). The purpose of this study is to evaluate different pattern of COPD assessment test (CAT) score between CB and non-CB patients. Methods: Patients were recruited from 45 centers in Korea, as part of the Korean COPD Subgroup Study cohort. CB was defined when sputum continued for at least 3 months. Results: Total 958 patients with COPD were eligible for analysis. Among enrolled patients, 328 (34.2%) were compatible with CB. The CAT score was significantly higher in patients with CB than non-CB, and each component of CAT score showed a similar result. CB was significantly associated with CAT score when adjusted with age, sex, modified Medical Research Council, and post-bronchodilator forced expiratory volume in 1 second. Each component of CAT score between patients with CB and non-CB showed different pattern according to Global Initiative for Chronic Obstructive Lung Disease grade. Conclusion: CAT score is significantly higher in patients with CB than non-CB. Each component of CAT score was significantly different between two groups.

Status of Studies Investigating Asthma-Chronic Obstructive Pulmonary Disease Overlap in Korea: A Review

  • Jo, Yong Suk
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권2호
    • /
    • pp.101-110
    • /
    • 2022
  • There is a considerable number of individuals who exhibit features of both asthma and chronic obstructive pulmonary disease (COPD), defined as asthma-COPD overlap (ACO). Many studies have reported that these patients have a greater burden of symptoms, including cough and dyspnea, and experience more exacerbations and hospitalizations than those with non-ACO COPD or asthma. Although diagnostic criteria for ACO have not yet been clearly established, their clinical significance remains to be determined. As interest in ACO grows, related studies have been conducted in South Korea as well. The present review summarizes ACO-related studies in South Korea to better understand Korean ACO patients and guide further research. Several cohort studies of asthma and COPD and population-based studies for ACO were reviewed and the key results from demographics, clinical features, lung function, biomarkers, treatment, and prognosis were summarized.

만성 폐쇄성 폐질환 환자의 급성 호흡기 감염에 대한 Clarithromycin의 임상 효과 (The Clinical Study of Clarithromycin for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease)

  • 김기범;신창진;이학준;정진홍;이관호;이현우
    • Journal of Yeungnam Medical Science
    • /
    • 제14권1호
    • /
    • pp.94-100
    • /
    • 1997
  • 1996년 9월부터 1996년 11월까지 영남대학교 의과대학 부속병원 내과에 입원한 급성 호흡기 감염으로 증상이 악화된 만성 폐쇄성 폐질환 환자 30명을 대상으로 clarithromycin 500mg을 하루 2회씩 증상이 호전될 때까지 경구로 10일동안 투여하여 다음과 같은 결과를 얻었다. 1) 30례 중 28례(93.4%)에서 완치 효과를 얻었고 2례에서는 증상의 호전이 있었으며 치료를 실패한 례는 없었다. 2) 임상적으로 3례(10%)에서 3일이내에 호전되었으며, 5일에서 12일사이에 대부분인 24례(80%)에서 호전되었으며 13일이후 호전된 경우는 3례(10%)였다. 3) 항생제를 투여한 기간은 4일이내가 1례였고, 5에서 12일사이가 5례, 13일 이상 투여하였던 경우가 24례였다. 4) 부작용으로는 1례(3.3%)에서 간기능 검사상 transaminase치의 경미한 상승이 발견되었으나 곧 회복되었다. 이상의 결과로 보아 clarithromycin은 만성 폐쇄성 폐질환 환자의 급성 호흡기 감염의 치료로 효과적이고 안전하게 사용될 수 있는 항생제로 생각된다.

  • PDF